HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Oct. 27, 2017 (HealthDay News) -- For medically uncontrolled uveitic glaucoma, the XEN-45 implant is effective, reducing the need for further surgery, according to a study published online Oct. 20 in Clinical & Experimental Ophthalmology.
Chelvin C.A. Sng, from Moorfields Eye Hospital in London, and colleagues examined the safety and efficacy of the XEN-45 collagen implant in eyes with uveitic glaucoma in an exploratory prospective case series. Participants included 24 patients with medically uncontrolled uveitic glaucoma who were implanted with XEN-45.
The researchers found that after implantation of XEN-45, further surgery was not needed in the 20 eyes in whom conventional glaucoma surgery was thought to be inevitable. There were reductions in the mean intraocular pressure (from 30.5±9.8 to 12.2±3.1 mmHg) and in the mean number of medications required (from 3.3±0.8 to 0.4±0.9) from baseline to 12 months (both P < 0.001). Complications included hypotony in one patient, which persisted beyond two months and required surgical revision, and blebitis, which developed in one patient. The 12-month cumulative probability of survival was 79.2 percent.
"The XEN-45 implant is effective for the treatment of patients with medically uncontrolled uveitic glaucoma. Potentially sight-threatening complications, including bleb-related ocular infection and persistent hypotony, may occur," the authors write.
Two authors disclosed financial ties to Allergan, which manufactures XEN-45, and one disclosed ties to Aquesys, an Allergan affiliate.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 29, 2022